Cong Lin, Zhou Zili
Department of Dermatology, Sichuan Second Hospital of T.C.M, Chengdu, Sichuan, China.
Department of Gastroenterology, Sichuan Second Hospital of T.C.M, Chengdu, Sichuan, China.
Alpha Psychiatry. 2024 Jun 1;25(3):369-374. doi: 10.5152/alphapsychiatry.2024.231352. eCollection 2024 Jun.
Insomnia is a common symptom in subhealthy states. In patients, long-term insomnia symptoms can lead to decreased immune function, even mental depression, thus seriously affecting quality of life. Therefore, this study aims to observe the therapeutic effect of huo li su (HLS) oral solution combined with zopiclone in the treatment of insomnia to find suitable drugs for treatment.
A total of 161 patients with insomnia from January 2017 to March 2022 were selected in this retrospective cohort study. The patients were divided into the observation (82 cases, receiving HLS oral solution and zopiclone) and control (79 cases, receiving zopiclone alone) groups in accordance with therapeutic drug administration. The differences in the scores of the 2 groups on the Sleep Disorder Scale (SDRS), Pittsburgh Sleep Quality Index (PSQI), Fatigue Inventory 14 (FS-14), and traditional Chinese medicine (TCM) syndromes before and after treatment were compared.
No significant differences in age, gender, disease duration, body mass index (BMI), and other general data were found between the 2 groups ( .05). The TCM syndrome, PSQI, FS-14, and SDRS scores before treatment of the 2 groups were not significantly different ( < .05). After 4 weeks of treatment, the TCM syndrome, PSQI, FS-14, and SDRS scores of the observation group were significantly lower than those of the control group.
HLS oral solution combined with zopiclone can effectively improve insomnia symptoms and is superior to zopiclone alone.
失眠是亚健康状态下的常见症状。在患者中,长期失眠症状可导致免疫功能下降,甚至出现精神抑郁,从而严重影响生活质量。因此,本研究旨在观察活力苏口服液联合佐匹克隆治疗失眠的疗效,以寻找合适的治疗药物。
本回顾性队列研究选取了2017年1月至2022年3月期间的161例失眠患者。根据治疗用药情况将患者分为观察组(82例,接受活力苏口服液和佐匹克隆治疗)和对照组(79例,仅接受佐匹克隆治疗)。比较两组治疗前后在睡眠障碍量表(SDRS)、匹兹堡睡眠质量指数(PSQI)、疲劳量表14(FS - 14)和中医证候方面的评分差异。
两组在年龄、性别、病程、体重指数(BMI)等一般资料方面无显著差异(P>0.05)。两组治疗前的中医证候、PSQI、FS - 14和SDRS评分无显著差异(P>0.05)。治疗4周后,观察组的中医证候、PSQI、FS - 14和SDRS评分显著低于对照组。
活力苏口服液联合佐匹克隆可有效改善失眠症状,且优于单用佐匹克隆。